Key facts
- Developer of rotavirus, shingles and herpes vaccine technology intended to serve the biotechnology industry.
- It has raised $284.2M; the latest was Later Stage VC in Dec 2025.
- Notable investors include Shenzhen Capital Group, Korea Investment Partners, GL Ventures, IDG Capital, Qianhai FoF — 16 tracked in total.
- Status: Privately Held (backing).
Free account
More of Maxvax Health with a free account
- ·The complete investor list: 16 names
- ·Watch Maxvax Health: the Monday email on marks, rounds and moves
Create free account
No card required
Funding rounds
No rounds on record
No funding rounds for Maxvax Health are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Pro members can request priority coverage with a 48-hour turnaround.
About Maxvax Health
Developer of rotavirus, shingles and herpes vaccine technology intended to serve the biotechnology industry. The company's vaccines aim to provide effective treatment for viral diseases, enabling healthcare professionals to deliver better treatments to their patients.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2016
- Employees
- 300
- Website
- maxvax.cn/
- Ownership
- Privately Held (backing)
Valuation — not yet priced
Maxvax Health doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.